BMRA
BIOMERICA (BMRA)
NASDAQ
$2.25+$0.010 (+0.45%)
Price as of Sep 11, 2026 7:30 PM EDT
  • $10.3M
    Market Cap
  • -24.83%
    1-Year Change
  • Medical Devices
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 72
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Biomerica Reports Second Quarter Fiscal 2026 Financial Results

Biomerica reported Q2 FY2026 results with net sales of $1.21M (down from $1.64M YoY) as the company transitions from legacy products to higher-margin diagnostic offerings. Key developments include a partnership with Henry Schein for inFoods® IBS commercialization, launch of an AI-backed Trigger Food Navigator tool, CMS establishment of a $300 Medicare reimbursement rate for inFoods® IBS, and Egyptian Drug Authority approval of the company's screening test portfolio. Operating expenses declined 4% YoY to $2.96M for the six-month period, and working capital improved by 14.7%.

01/14/2026, 5:17 PM • GlobeNewswire

Biomerica Reports Fiscal 2025 Year End Results

Biomerica reported modest financial performance with $5.3 million in net sales, reduced operating expenses by $1.3 million, and improved operating loss by 19%. The company focused on strategic growth in diagnostic tests, particularly inFoods® IBS, and expanded international market presence.

08/29/2025, 5:12 PM • GlobeNewswire

Peers

Statistics

More
Day Range
$2.13
$2.29
$2.24
1-Year Range
$1.49
$3.20
$2.24
Latest Close$2.24
Change
+$0.01 (+0.45%)
Volume11,937
Market Cap$10.3M
Shares Outstanding4.6M
P/E (TTM)-1.73
Diluted EPS (TTM)-$1.30
Enterprise Value$9.5M

Information as of 09/11/2026

Company Profile

$10.3M
Market Cap
-$3.8M
Net Income
Sector: Healthcare
Industry: Medical Devices
17571 Von Karman Avenue, Irvine, CA, United States, 92614
949 645 2111

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties. In addition, the company commercializes inFoods IBS product through physician-directed and laboratory-based channels, such as third-party reimbursement pathways. Further, it is involved in the development and optimization of immunoassays, enzyme-linked immunosorbent assays, rapid diagnostic tests, and related diagnostic technologies; and research, development, commercialization of diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. Additionally, the company offers EZ detect colon disease home test; Aware Breast Self-Exam product; and hp+detect, a diagnostic test designed to detect Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Key Executives

  • Gary Lu
  • Zackary S. Irani
  • Allen C. Barbieri
  • Lucy Liu
  • Scott Madel

Current Ownership Distribution

  • Institutions42.1M (69.50%)
  • Mutual Funds14.6M (24.17%)
  • Insiders3.8M (6.32%)
  • Other0 (0.00%)